Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of +26.92% and +1.18%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced five-year ALIGN3D results on September 17, adding longer-term evidence for the Lapiplasty bunion-correction procedure. The final analysis included 137 of 173 treated patients, or approximately 79% of the original group. Reported radiographic recurrence was 0.8% when defined as a hallux valgus angle greater than 20 degrees and 5.3% using […]
Treace Medical outlook: revenue declines, Lapiplasty losing share, margins compressing, and EBITDA delayed. Click for more on TMCI stock.
This is the newest page. Registered accounts read further back.